Treace Medical Concepts (TMCI) Stock Forecast & Price Target

Compare

106 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TMCI Analyst Ratings

Moderate Buy

2 Buy

5 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Treace

Medical Concepts

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TMCI Stock 12 Month Forecast

Average Price Target

$10.35

▲(87.84%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Treace Medical Concepts in the last 3 months. The average price target is $10.35 with a high forecast of $14.50 and a low forecast of $8.60. The average price target represents a 87.84% change from the last price of $5.51.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","6":"$6","9":"$9","12":"$12","15":"$15"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6,9,12,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.34,7.890769230769231,8.441538461538462,8.992307692307692,9.543076923076923,10.093846153846155,10.644615384615385,11.195384615384615,11.746153846153845,12.296923076923077,12.847692307692308,13.39846153846154,13.94923076923077,{"y":14.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.34,7.571538461538461,7.803076923076923,8.034615384615385,8.266153846153847,8.497692307692308,8.72923076923077,8.96076923076923,9.192307692307692,9.423846153846153,9.655384615384616,9.886923076923077,10.118461538461538,{"y":10.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.34,7.436923076923077,7.533846153846154,7.63076923076923,7.727692307692307,7.8246153846153845,7.921538461538462,8.018461538461539,8.115384615384615,8.212307692307691,8.30923076923077,8.406153846153845,8.503076923076923,{"y":8.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.19,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.86,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.17,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.41,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.78,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.78,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.50

Average Price Target$10.35

Lowest Price Target$8.60

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$5.5

Hold

-0.18%

Downside

Reiterated

06/05/25

The score reflects significant financial challenges due to persistent losses and cash flow issues, compounded by bearish technical indicators and valuation concerns. Earnings call showed some operational improvements, but overall growth remains modest.

Richard NewitterTruist Financial

Truist Financial

―

Hold

―

Reiterated

05/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: InflaRx (NASDAQ: IFRX), Treace Medical Concepts (NASDAQ: TMCI) and Amarin (NASDAQ: AMRN)

Danielle AntalffyUBS

UBS

$10→$8.6

Hold

56.08%

Upside

Reiterated

05/09/25

Treace Medical price target lowered to $8.60 from $10 at UBSTreace Medical price target lowered to $8.60 from $10 at UBS

Rick WiseStifel Nicolaus

Stifel Nicolaus

Hold

63.34%

Upside

Reiterated

05/09/25

Stifel Nicolaus Reaffirms Their Hold Rating on Treace Medical Concepts (TMCI)

Kallum TitchmarshMorgan Stanley

Morgan Stanley

$10

Hold

81.49%

Upside

Reiterated

05/09/25

Cautious Hold Rating for Treace Medical Concepts Amid Mixed Outlook and Revenue Uncertainty

Ryan ZimmermanBTIG

BTIG

$14→$11

Buy

99.64%

Upside

Reiterated

05/09/25

BTIG Sticks to Its Buy Rating for Treace Medical Concepts (TMCI)

Ben HaynorLake Street

Lake Street

$14.5

Buy

163.16%

Upside

Reiterated

05/09/25

Treace Medical Concepts (TMCI) Receives a Buy from Lake Street

Lilia-Celine (Lily) LozadaJ.P. Morgan

Not Ranked

J.P. Morgan

$10→$9

Hold

63.34%

Upside

Reiterated

05/09/25

Treace Medical Concepts Inc (TMCI) PT Lowered to $9 at JPMorganJPMorgan analyst Lilia-Celine B Lozada lowered the price target on Treace Medical Concepts Inc (NASDAQ: TMCI) to $9.00 (from $10.00) while maintaining a Neutral rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$5.5

Hold

-0.18%

Downside

Reiterated

06/05/25

Richard NewitterTruist Financial

Truist Financial

―

Hold

―

Reiterated

05/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: InflaRx (NASDAQ: IFRX), Treace Medical Concepts (NASDAQ: TMCI) and Amarin (NASDAQ: AMRN)

Danielle AntalffyUBS

UBS

$10→$8.6

Hold

56.08%

Upside

Reiterated

05/09/25

Treace Medical price target lowered to $8.60 from $10 at UBSTreace Medical price target lowered to $8.60 from $10 at UBS

Rick WiseStifel Nicolaus

Stifel Nicolaus

Hold

63.34%

Upside

Reiterated

05/09/25

Stifel Nicolaus Reaffirms Their Hold Rating on Treace Medical Concepts (TMCI)

Kallum TitchmarshMorgan Stanley

Morgan Stanley

$10

Hold

81.49%

Upside

Reiterated

05/09/25

Cautious Hold Rating for Treace Medical Concepts Amid Mixed Outlook and Revenue Uncertainty

Ryan ZimmermanBTIG

BTIG

$14→$11

Buy

99.64%

Upside

Reiterated

05/09/25

BTIG Sticks to Its Buy Rating for Treace Medical Concepts (TMCI)

Ben HaynorLake Street

Lake Street

$14.5

Buy

163.16%

Upside

Reiterated

05/09/25

Treace Medical Concepts (TMCI) Receives a Buy from Lake Street

Lilia-Celine (Lily) LozadaJ.P. Morgan

Not Ranked

J.P. Morgan

$10→$9

Hold

63.34%

Upside

Reiterated

05/09/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Treace Medical Concepts

1 Month

xxx

Success Rate

7/17 ratings generated profit

Average Return

+0.57%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 41.18% of your transactions generating a profit, with an average return of +0.57% per trade.

3 Months

xxx

Success Rate

9/17 ratings generated profit

Average Return

-2.57%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of -2.57% per trade.

1 Year

Ryan ZimmermanBTIG

Success Rate

2/17 ratings generated profit

Average Return

-35.61%

reiterated a buy rating last month

Copying Ryan Zimmerman's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -35.61% per trade.

2 Years

xxx

Success Rate

0/17 ratings generated profit

Average Return

-67.49%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -67.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TMCI Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TMCI has received 3 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. TMCI average Analyst price target in the past 3 months is 10.35.

Each month's total comprises the sum of three months' worth of ratings.

TMCI Financial Forecast

TMCI Earnings Forecast

Next quarter’s earnings estimate for TMCI is -$0.28 with a range of -$0.31 to -$0.26. The previous quarter’s EPS was -$0.25. TMCI beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year TMCI has Outperformed its overall industry.

TMCI Sales Forecast

Next quarter’s sales forecast for TMCI is $47.08M with a range of $47.00M to $47.14M. The previous quarter’s sales results were $52.57M. TMCI beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 57.81% of the time in the same period. In the last calendar year TMCI has Outperformed its overall industry.

TMCI Stock Forecast FAQ

What is TMCI’s average 12-month price target, according to analysts?

Based on analyst ratings, Treace Medical Concepts’s 12-month average price target is 10.35.

What is TMCI’s upside potential, based on the analysts’ average price target?

Treace Medical Concepts has 87.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TMCI a Buy, Sell or Hold?

Treace Medical Concepts has a consensus rating of Moderate Buy which is based on 2 buy ratings, 5 hold ratings and 0 sell ratings.

What is Treace Medical Concepts’s price target?

The average price target for Treace Medical Concepts is 10.35. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.50 ,the lowest forecast is $8.60. The average price target represents 87.84% Increase from the current price of $5.51.

What do analysts say about Treace Medical Concepts?

Treace Medical Concepts’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of TMCI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Treace Medical Concepts (TMCI) Stock Forecast & Price Target

TMCI Analyst Ratings

TMCI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Treace Medical Concepts

TMCI Analyst Recommendation Trends

TMCI Financial Forecast

TMCI Earnings Forecast

TMCI Sales Forecast

TMCI Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts